Results 161 to 170 of about 1,043,535 (340)

Bacterial antagonists and hexanal-induced systemic resistance of mango fruits against Lasiodiplodia theobromae causing stem-end rot [PDF]

, 2016
S. Parthasarathy, G. Thiribhuvanamala, K. S. Subramanian, Prabakar Kuppusamy   +3 more
openalex   +1 more source

The marionette mechanism of domain–domain communication in the antagonist, agonist, and coactivator responses of the estrogen receptor

, 2023
Xun Chen, Shikai Jin, Mingchen Chen, Carlos Bueno, Peter G. Wolynes   +4 more
openalex   +2 more sources

Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques [PDF]

, 2020
Zheyi Li, MRS. SUWERSH KHANNA, Samantha L. Grimley, Paula Ellenberg, Christopher A. Gonelli, Wen Shi Lee, Thakshila Amarasena, Anthony D. Kelleher, Damian F. J. Purcell, Stephen J. Kent, Charani Ranasinghe   +10 more
openalex   +1 more source

Oligodendrocyte development and myelin sheath formation are regulated by the antagonistic interaction between the Rag‐Ragulator complex and TFEB [PDF]

, 2023
Ellen L. Bouchard, Ana M. Meireles, William S. Talbot   +2 more
openalex   +1 more source

Calcium antagonists [PDF]

Anaesthesia, 1983
openaire   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

A Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy Volunteers

, 2014
Rachel A. Gibson, Jon Robertson, Harshna Mistry, Stewart W. McCallum, Disala Fernando, Melody Wyres, Gil Yosipovitch   +6 more
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

The effect of ovarian stimulation on aneuploidy of early aborted tissues and preimplantation blastocysts: comparison of the GnRH agonist long protocol with the GnRH antagonist protocol

, 2022
Jun Wang, Jing Zhang, Nan Zhao, Yuan Ma, Xiyi Wang, Xingqing Gou, Ying Ju, Hengde Zhang, Shuqiang Chen, Xiaohong Wang   +9 more
openalex   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source